

# Perlmutter Cancer Center

NYU Langone Health Presentations at ASCO  
May 31, 2026

**Session:** Melanoma/Skin Cancers

**Title:** Intismeran autogene to induce de novo neoantigen-specific T cells as adjuvant therapy in melanoma.

**Senior Author:** Janice Mehnert, MD

**Time:** 9:00AM-12:00PM

**Location:** Hall A - Posters and Exhibits

**Abstract Number:** 9564

**Session:** Lung Cancer—Non-Small Cell Metastatic

**Title:** ALPACCA: Phase 3 trial of firmonertinib vs investigator's choice of EGFR inhibitor as first-line treatment for locally advanced or metastatic NSCLC with EGFR P-loop and alpha c-helix compressing (PACC) uncommon mutations (FURMO-006)

**Co-Author:** Elaine Shum, MD

**Time:** 9:00AM-12:00PM

**Location:** Hall A - Posters and Exhibits

**Abstract Number:** TPS8675

**Session:** Lung Cancer—Non-Small Cell Metastatic

**Title:** Initial safety and efficacy of A2B694, a logic-gated mesothelin (MSLN)-targeted Tmod chimeric antigen receptor T-cell (CAR T) therapy in patients with advanced solid tumors with HLA-A\*02 loss of heterozygosity (LOH)

**Senior Author:** Salman Punekar, MD

**Time:** 9:00AM-12:00PM

**Location:** Hall A - Posters and Exhibits

**Abstract Number:** 8579

**Session:** Lung Cancer—Non-Small Cell Metastatic

**Title:** FF-10832 liposomal gemcitabine monotherapy or combination with pembrolizumab in patients with advanced non-small cell lung cancer

**Co-Author:** Salman Punekar, MD

**Time:** 9:00AM-12:00PM

**Location:** Hall A - Posters and Exhibits

**Abstract Number:** 8560

**Session:** Lung Cancer—Non-Small Cell Metastatic

**Title:** COPERNICUS, a pragmatic phase 2b study of first-line (1L) subcutaneous (SC) amivantamab (ami) + lazertinib (laz) with supportive care in EGFR-mutated advanced NSCLC: Early safety results

**Co-Author:** Joshua K. Sabari, MD

**Time:** 9:00AM-12:00PM

**Location:** Hall A - Posters and Exhibits

**Abstract Number:** 8613

**Session:** Lung Cancer—Non-Small Cell Metastatic

**Title:** COPERNICUS, a pragmatic phase 2b study of subcutaneous (SC) amivantamab (ami) + chemotherapy (chemo) with enhanced dermatologic adverse event (AE) prophylaxis in EGFR-mutated advanced NSCLC: Interim results

**Co-Author:** Joshua K. Sabari, MD

**Time:** 9:00AM-12:00PM

**Location:** Hall A - Posters and Exhibits

**Abstract Number:** 8614

**Session:** Lung Cancer—Non-Small Cell Metastatic

**Title:** PRO results from the Beamion LUNG-1 trial in treatment-naïve patients with HER2-mutant advanced NSCLC

**Co-Author:** Joshua K. Sabari, MD

**Time:** 9:00AM-12:00PM

**Location:** Hall A - Posters and Exhibits

**Abstract Number:** 8616

**Session:** Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

**Title:** Beamion LUNG-3: Zongertinib in resectable HER2-mutant NSCLC

**Co-Author:** Elaine Shum, MD

**Time:** 9:00AM-12:00PM

**Location:** Hall A - Posters and Exhibits

**Abstract Number:** TPS8129

**Session:** Genitourinary Cancer—Prostate, Testicular, and Penile

**Title:** Dissecting metastatic castration-resistant prostate cancer using regulatory network analysis of tumor transcriptomes

**First Author:** Aaron Griffin, MD

**Senior Author:** David Wise, MD  
**Time:** 9:00AM-12:00PM  
**Location:** Hall A - Posters and Exhibits  
**Abstract Number:** 5074

**Session:** Lung Cancer - Non-Small Cell Metastatic  
**Title:** Efficacy, safety, and cytokine profiling with addition of the toll-like receptor (TLR) 7/8 dual agonist EIK1001 to standard of care (SOC) first-line (1L) therapy: The phase 2 TeLuRide-005 trial in stage 4 NSCLC.  
**Co-Author:** Marissa Rybstein, MD  
**Time:** 9:00AM-12:00PM  
**Location:** Hall A - Posters and Exhibits  
**Abstract Number:** 8568

**Session:** Lung Cancer - Non-Small Cell Metastatic  
**Title:** A phase 2/3 study of EIK1001 in combination with pembrolizumab and chemotherapy in participants with stage 4 non-small cell lung cancer (NSCLC) (TeLuRide-008)  
**Co-Author:** Marissa Rybstein, MD  
**Time:** 9:00AM-12:00PM  
**Location:** Hall A - Posters and Exhibits  
**Abstract Number:** TPS8668

**Session:** Lung Cancer - Non-small cell local-regional/small cell/other thoracic cancers  
**Title:** Trends in Income-related lung cancer disparities since the introduction of the USPSTF Screening Guidelines  
**First Author:** Tyler Healy, MD  
**Senior Author:** Daniel Becker, MD  
**Time:** 9:00AM-12:00PM  
**Location:** Hall A - Posters and Exhibits  
**Abstract Number:** 8072

**Session:** Genitourinary Cancer—Kidney and Bladder  
**Title:** Assessing responses to UGN-102 across EORTC recurrence score groups in patients with recurrent low-grade intermediate-risk NMIBC (ENVISION trial)  
**Co-Author:** William Huang, MD  
**Time:** 9:00AM-12:00PM  
**Location:** Hall A - Posters and Exhibits  
**Abstract Number:** 4601

**Session:** Head and Neck Cancer  
**Title:** A phase 2 study of ipatasertib in combination with pembrolizumab for first-line treatment

of recurrent or metastatic squamous cell cancer of the head and neck

**Co-Author:** Zujun Li, MD

**Time:** 10:00-10:12AM

**Location:** S100a

**Abstract Number:** 6006

**Session:** Hematologic Malignancies—Plasma Cell Dyscrasia

**Title:** Daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) in patients (pts) with newly diagnosed multiple myeloma (NDMM): Final analysis of transplant-ineligible (TIE) pts in the phase 3 CEPHEUS study

**Co-Author:** Marc Braunstein, MD, PhD

**Time:** 10:21-10:27AM

**Location:** E450a

**Abstract Number:** 7513

**Session:** Plenary Session

**Title:** Daraxonrasib, a RAS(ON) multi-selective inhibitor vs chemotherapy in previously treated metastatic pancreatic adenocarcinoma (mPDAC): Primary and final analysis from the phase 3 RASolute 302 study

**Co-Author:** Paul Oberstein, MD

**Time:** 3:21-3:33PM

**Location:** Hall B1

**Abstract Number:** LBA5